Testing IBI311 for inactive thyroid eye disease symptoms
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a medication called IBI311 for people with inactive thyroid eye disease that still causes bothersome symptoms like double vision or trouble closing the eyes. The goal is to see if it helps improve these problems safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thyroid eye disease (also called TED or Graves' eye disease).
- Your eye symptoms are moderate to severe (like significant bulging, double vision, or eyelid problems).
- Your eye disease is currently stable and not actively getting worse (your doctor will check this).
- You have ongoing problems like double vision, trouble closing your eyes, or you need surgery for your eyes.
- You are willing to try a new treatment for your eye condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
This study uses eye tracking to compare how people with thyroid eye disease move their eyes and pay attention to visual cues. It may help researchers understand eye movement problems better.
This trial tests a two-step treatment for active, moderate-to-severe thyroid eye disease (TAO). You will first receive hormone therapy, followed by a drug called IBI311. The goal is to see if this sequence works better for people who have not had steroid treatment before.
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
This study tests an investigational drug, KHN939, for people with moderate-to-severe inactive thyroid eye disease (also called Graves' eye disease). The goal is to see if the drug can improve symptoms such as bulging eyes and double vision. Participation lasts for several months and involves regular check-ups.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
Hear when a new Thyroid Associated Ophthalmopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.